111753-73-2

111753-73-2 structure

Name: Satigrel
Chemical Name: 4-cyano-5,5-bis(4-methoxyphenyl)pent-4-enoic acid
CAS Number: 111753-73-2
Molecular Formula: C₂₀H₁₉NO₄
Molecular Weight: 337.36900
Catalog: Signaling Pathways GPCR/G Protein Prostaglandin Receptor
Create Date: 2018-04-23 08:00:00
Modify Date: 2025-08-25 20:30:31
Satigrel (E5510) is a potent inhibitor of platelet aggregation. Satigrel inhibits collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC50: 0.081 μM) and PGHS2 (IC50: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC50: 15.7 μM, 39.8 μM and 62.4 μM, respectively)[1].

Name	4-cyano-5,5-bis(4-methoxyphenyl)pent-4-enoic acid
Synonyms	E5510 5,5-Bis(4-methoxyphenyl)-4-cyano-4-pentenoic acid Satigrel 4-Cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid 4-Pentenoic acid,4-cyano-5,5-bis(4-methoxyphenyl) 4-Pentenoic acid,5,5-bis(4-methoxyphenyl)-4-cyano

Description	Satigrel (E5510) is a potent inhibitor of platelet aggregation. Satigrel inhibits collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC50: 0.081 μM) and PGHS2 (IC50: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC50: 15.7 μM, 39.8 μM and 62.4 μM, respectively)[1].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> GPCR/G Protein >> Prostaglandin Receptor
References	[1]. N Nagakura, et al. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Biol Pharm Bull. 1996 Jun;19(6):828-33.